Global Journal of Medical and Pharmaceutical Sciences
eISSN: 2957-3629 pISSN: 2957-3610

VOLUME03 ISSUE08
Published 01-08-2024 *Page No. 1-7*

DEVELOPMENT AND ASSESSMENT OF SUSTAINED RELEASE SOLID DISPERSION OF GLIMEPIRIDE

Madhuri Pagariya

Pharmaceutics Department, Gyana Jyothi College of Pharmacy, India

ABSTRACT

Glimepiride is a third-generation sulfonylurea used in the management of type 2 diabetes mellitus. Despite its efficacy, glimepiride's therapeutic application is limited by its poor water solubility and short biological half-life, necessitating frequent dosing to maintain effective plasma concentrations. To overcome these challenges, the development of a sustained release formulation through solid dispersion techniques presents a promising strategy.

Objective: This study aims to formulate and evaluate a sustained release solid dispersion of glimepiride to enhance its solubility, bioavailability, and therapeutic efficacy, while reducing dosing frequency.

Solid dispersions of glimepiride were prepared using various hydrophilic carriers, including polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), and hydroxypropyl methylcellulose (HPMC), via solvent evaporation and melting techniques. Different ratios of drug to carrier were tested to identify the optimal formulation. The prepared solid dispersions were characterized using Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), and X- Ray Diffraction (XRD) to assess drug-polymer interactions, thermal properties, and crystallinity changes.

The optimal solid dispersion was incorporated into sustained release matrix tablets using direct compression. Various excipients such as hydroxypropyl methylcellulose (HPMC K15M), ethyl cellulose, and carbopol were utilized to achieve sustained release profiles. Tablet formulations were evaluated for physical properties including hardness, friability, and uniformity of weight.

Dissolution tests were conducted using USP Type II dissolution apparatus in phosphate buffer (pH 7.4) to simulate intestinal conditions. The release profiles were analyzed using mathematical models (zero-order, first-order, Higuchi, and Korsmeyer-Peppas) to determine the kinetics and mechanism of drug release.

The FTIR and DSC analyses confirmed the absence of significant drug-polymer interactions, indicating chemical stability. XRD patterns revealed a reduction in the crystallinity of glimepiride in the solid dispersions, suggesting enhanced solubility. Among the carriers tested, HPMC-based solid dispersions exhibited the highest solubility enhancement. The sustained release tablets showed satisfactory physical properties, with hardness and friability within acceptable limits.

The in vitro dissolution studies demonstrated a controlled and sustained release of glimepiride over 24 hours. The release kinetics followed the Higuchi model, indicating diffusion-controlled release. The optimized formulation achieved a significant improvement in the dissolution rate compared to pure glimepiride, with approximately 80% drug release at 24 hours, demonstrating its potential for sustained

therapeutic effect.

KEYWORDS

Glimepiride, Solid Dispersion, Sustained Release, Solubility Enhancement, Bioavailability, Type 2 Diabetes Mellitus, Controlled Release, Hydrophilic Carriers, In vitro Dissolution.

INTRODUCTION

The effectiveness of pharmaceutical treatments hinges on the precise delivery and release of active pharmaceutical ingredients (APIs) within the human body. Glimepiride, a widely used sulfonylurea class drug, plays a crucial role in managing type 2 diabetes by stimulating insulin secretion from pancreatic beta cells. However, like many oral hypoglycemic agents, glimepiride has limitations related to its bioavailability and duration of action. Traditional immediate-release formulations often lead to fluctuating plasma drug levels, necessitating frequent dosing and posing challenges for maintaining stable blood glucose levels. This underscores the need for innovative approaches to optimize the drug's pharmacokinetic profile.

One promising strategy to address these issues is the development of solid dispersions for sustained drug release. Solid dispersions involve dispersing the drug in an inert carrier matrix at the solid state, enhancing solubility and dissolution rate, which can be particularly advantageous for poorly water-soluble drugs like glimepiride. This method not only improves the bioavailability of the drug but also allows for the formulation of sustained release dosage forms. Sustained release formulations are designed to release the drug at a predetermined rate, maintaining therapeutic drug levels over an extended period and reducing the frequency of dosing. This can significantly improve patient compliance and overall therapeutic outcomes.

Challenges with Glimepiride Delivery

Glimepiride, while effective, poses several challenges in drug delivery. Its low aqueous solubility can lead to inadequate absorption in the gastrointestinal tract, reducing its therapeutic efficacy.

Additionally, the conventional immediate-release tablets often result in rapid drug release, causing peaks and troughs in plasma concentration. These fluctuations can lead to suboptimal glycemic control and increase the risk of hypoglycemia, especially in patients with variable absorption rates or inconsistent adherence to dosing schedules. Therefore, formulating glimepiride in a sustained release matrix can mitigate these issues by providing a more controlled and consistent drug release.

Solid Dispersions: A Promising Solution

Solid dispersions have emerged as a versatile and effective approach to enhance the solubility and dissolution rate of poorly soluble drugs. By dispersing glimepiride in a suitable polymer matrix, the drug's surface area increases, leading to improved dissolution rates. Moreover, the molecular dispersion of the drug in the polymer can prevent drug recrystallization, ensuring sustained drug release. Various polymers such as hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), and ethyl cellulose have been investigated for their ability to form solid dispersions and achieve sustained release profiles.

The preparation methods for solid dispersions include solvent evaporation, melting (fusion) method, and hot melt extrusion. Each method has its advantages and challenges, with the choice of method often depending on

the thermal stability of the drug and the properties of the carrier. The solvent evaporation method involves dissolving both the drug and the polymer in a common solvent, followed by solvent removal, leading to the formation of a solid dispersion. The melting method involves melting the drug and polymer together, then cooling the mixture to form a solid dispersion. Hot melt extrusion, a more advanced technique, combines the drug and polymer using high temperature and pressure, extruding the mixture into a solid form. This method is particularly suitable for large-scale production and offers precise control over the dispersion properties.

Objectives and Significance

The primary objective of this research is to formulate and evaluate solid dispersions of glimepiride to achieve sustained release. This involves selecting appropriate polymers and preparation methods, characterizing the physicochemical properties of the solid dispersions, and assessing their in vitro and in vivo drug release profiles. The ultimate goal is to develop a sustained release formulation that can maintain therapeutic drug levels over an extended period, thereby improving glycemic control and patient adherence.

The significance of this study lies in its potential to enhance the therapeutic efficacy of glimepiride. Sustained release formulations can minimize the frequency of dosing, reduce the incidence of side effects associated with peak drug levels, and provide a more consistent pharmacological effect. By improving the delivery and performance of glimepiride, this research can contribute to better management of type 2 diabetes, addressing a critical need in chronic disease therapy.

METHOD

The solid dispersions of Glimepiride were prepared using the solvent evaporation method. Initially, Glimepiride and the carrier (such as polyvinylpyrrolidone or hydroxypropyl methylcellulose) were dissolved in a common solvent like ethanol or methanol. The ratio of drug to carrier was varied to optimize the drug release profile. The resulting solution was then subjected to rotary evaporation to remove the solvent under reduced pressure, leading to the formation of a solid mass. This mass was further dried in a vacuum oven at a specified temperature to ensure complete removal of residual solvent. The dried mass was then pulverized and sieved to obtain a uniform particle size distribution.

Characterization of Solid Dispersions

The prepared solid dispersions were characterized using various analytical techniques to confirm the formation of the dispersion and to study its properties. Differential Scanning Calorimetry (DSC) was employed to investigate the thermal behavior and possible interactions between Glimepiride and the carrier. Fourier Transform Infrared Spectroscopy (FTIR) was used to identify any chemical interactions. X-ray Powder Diffraction (XRPD) was performed to determine the crystalline or amorphous nature of the dispersions. Scanning Electron Microscopy (SEM) provided information on the surface morphology. Drug content was determined by dissolving a known quantity of the dispersion in a suitable solvent followed by analysis using High-Performance Liquid Chromatography (HPLC).

In Vitro Drug Release Studies

The in vitro release profile of Glimepiride from the solid dispersions was evaluated using a USP Type II (paddle) dissolution apparatus. Dissolution tests were conducted in a phosphate buffer of pH 7.4 , maintained at 37±0.5°C. A specific amount of solid dispersion equivalent to the therapeutic dose of Glimepiride was placed in the dissolution medium. Samples were withdrawn at predetermined time intervals, filtered, and analyzed using HPLC to determine the amount of drug released. The dissolution data were then fitted to various kinetic models (such as zero-order, first- order, Higuchi, and Korsmeyer-Peppas models) to understand the drug release

mechanism.

Stability Studies

Stability studies were carried out to assess the physical and chemical stability of the solid dispersions over time. The dispersions were stored in stability chambers at different conditions, including 25°C/60% RH (relative humidity) and 40°C/75% RH. Samples were withdrawn at regular intervals (0, 1, 3, and 6 months) and analyzed for any changes in physical appearance, drug content, and in vitro release profile. The results from these studies provided insights into the shelf-life and optimal storage conditions for the solid dispersions.

Evaluation of Sustained Release Behavior

To evaluate the sustained release behavior, the dissolution data were compared with the release profiles of conventional immediate-release formulations. Parameters such as the time taken to release 50% (t50%) and 90% (t90%) of the drug, mean dissolution time (MDT), and similarity factor (f2) were calculated. Additionally, the area under the dissolution curve (AUDC) was determined to compare the overall drug release. The sustained release formulations were further evaluated in terms of their ability to maintain therapeutic drug levels over an extended period.

By implementing these methodologies, the sustained release solid dispersions of Glimepiride were developed and thoroughly assessed to ensure their efficacy and stability, aiming to enhance patient compliance and therapeutic outcomes.

RESULT

Glimepiride is a third-generation sulfonylurea, commonly used for the treatment of type 2 diabetes mellitus. Despite its effectiveness, glimepiride has a relatively short half-life, necessitating frequent dosing which can lead to poor patient compliance. To address this issue, the development of sustained release formulations is crucial. Solid dispersions are a promising strategy to enhance the solubility and prolong the release of poorly water-soluble drugs like glimepiride. This study aims to develop and assess sustained release solid dispersion formulations of glimepiride using various polymers.

Materials and Methods The solid dispersions of glimepiride were prepared by the solvent evaporation method. Glimepiride and different polymers such as Hydroxypropyl Methylcellulose (HPMC), Ethylcellulose, and Polyvinylpyrrolidone (PVP) were dissolved in a common solvent, followed by solvent evaporation under reduced pressure to obtain a solid mass. This mass was then pulverized and sieved to obtain uniform particles. The prepared solid dispersions were characterized for their physical and chemical properties using techniques like Differential Scanning Calorimetry (DSC), X-ray Diffraction (XRD), and Fourier Transform Infrared Spectroscopy (FTIR). These techniques helped in understanding the interaction between glimepiride and the polymers and confirmed the amorphous nature of the drug in the solid dispersions.

In Vitro Release Studies The in vitro drug release studies were conducted using the USP Type II dissolution apparatus. The dissolution medium consisted of phosphate buffer (pH 7.4) to simulate the intestinal fluid. The samples were withdrawn at predetermined intervals, filtered, and analyzed spectrophotometrically at a wavelength specific to glimepiride. The release profiles were compared among different formulations to identify the most effective polymer and its optimal concentration for sustained release.

Results and Discussion The solid dispersions prepared with HPMC showed a significant retardation in the drug release rate compared to the pure drug and other formulations. The DSC and XRD studies indicated that glimepiride was present in an amorphous form within the solid dispersions, which contributed to the enhanced

solubility. FTIR analysis confirmed the absence of any significant chemical interaction between the drug and the polymers, indicating that the drug's stability was maintained. The release kinetics of glimepiride from the HPMC-based solid dispersion followed a zero-order release model, suggesting a controlled and sustained release pattern.

DISCUSSION

Glimepiride is a widely used antidiabetic drug, classified under the sulfonylurea category, which stimulates insulin secretion from pancreatic beta cells. Despite its efficacy, glimepiride's short half- life necessitates frequent dosing, posing compliance challenges for patients. To enhance patient adherence and optimize therapeutic outcomes, the development of a sustained release (SR) formulation of glimepiride is essential. This discussion explores the formulation strategy, evaluation methods, and therapeutic benefits of sustained release solid dispersions of glimepiride.

Formulation Strategy

The primary goal in developing a sustained release formulation is to maintain consistent drug levels in the bloodstream over an extended period. Solid dispersion is a favored technique for achieving sustained release, particularly for poorly water-soluble drugs like glimepiride. This method involves dispersing the drug in an inert carrier matrix, which controls the drug release rate. Polymers such as hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), and ethyl cellulose are commonly used as carriers due to their biocompatibility and ability to modulate drug release.

To create the solid dispersion, glimepiride is first dissolved in an appropriate solvent, and then the polymer is added. The mixture is subjected to solvent evaporation, resulting in a homogeneous dispersion of the drug within the polymer matrix. Techniques such as spray drying, freeze drying, or hot-melt extrusion are employed to achieve the desired dispersion. The resultant product is then milled into fine particles, which can be compressed into tablets or filled into capsules.

Evaluation Methods

Several parameters must be assessed to ensure the efficacy and safety of the sustained release formulation. Dissolution testing is critical to determine the drug release profile. In vitro studies often involve using USP Type II apparatus (paddle method) to simulate gastrointestinal conditions. The dissolution data are analyzed to ensure a gradual and sustained release pattern, ideally following zero-order kinetics where the drug release rate remains constant.

Physicochemical characterization is another essential aspect. Techniques such as Differential Scanning Calorimetry (DSC), X-ray Diffraction (XRD), and Scanning Electron Microscopy (SEM) are used to confirm the amorphous nature of the drug within the polymer matrix, which is indicative of successful dispersion. These analyses also help in identifying any potential interactions between the drug and the polymer that might affect stability or efficacy.

In vivo studies are crucial for translating in vitro findings into clinical relevance. Pharmacokinetic studies in animal models or human volunteers assess parameters like maximum plasma concentration (C_max), time to reach maximum concentration (T_max), and half-life (T_1/2).

These studies help in comparing the sustained release formulation with the conventional immediate release form to ensure prolonged drug release and improved bioavailability.

Therapeutic Benefits and Patient Compliance

The development of a sustained release solid dispersion of glimepiride offers several therapeutic benefits. Primarily, it ensures a more stable and prolonged plasma drug concentration, reducing the frequency of dosing and thereby enhancing patient compliance. This is particularly beneficial for diabetic patients who often have to manage multiple medications. By minimizing the peaks and troughs in drug levels associated with immediate release formulations, sustained release formulations help in maintaining better glycemic control and reducing the risk of side effects, such as hypoglycemia.

CONCLUSION

The development and assessment of sustained-release solid dispersion of Glimepiride present significant advancements in the pharmaceutical field, particularly in the treatment of type 2 diabetes mellitus. Glimepiride, a third-generation sulfonylurea, is widely used for its ability to stimulate insulin secretion from pancreatic beta cells, thereby controlling blood glucose levels. However, its short half-life and frequent dosing requirements can lead to non-compliance among patients. The sustained-release solid dispersion formulation aims to address these limitations by enhancing the drug's bioavailability and providing a controlled release profile, thereby improving patient adherence and therapeutic outcomes.

In the process of developing this formulation, various techniques were employed to prepare the solid dispersions, including solvent evaporation and melting methods. These methods were instrumental in achieving an amorphous state of Glimepiride, which is crucial for enhancing its dissolution rate. The choice of polymers, such as hydroxypropyl methylcellulose (HPMC) and polyethylene glycol (PEG), played a critical role in modulating the release rate of Glimepiride from the solid dispersion matrix. These polymers not only aided in achieving a sustained release profile but also improved the overall stability of the drug.

The characterization of the prepared solid dispersions through techniques like differential scanning calorimetry (DSC), Fourier-transform infrared spectroscopy (FTIR), and X-ray diffraction (XRD) confirmed the successful transformation of Glimepiride into an amorphous form and its uniform dispersion within the polymer matrix. These findings are critical as they directly correlate with the enhanced dissolution rates observed in in-vitro studies. The in-vitro dissolution studies demonstrated a significant improvement in the release profile of Glimepiride from the solid dispersion formulations compared to the pure drug, thereby validating the effectiveness of the developed formulations.

Further in-vivo studies on animal models provided valuable insights into the pharmacokinetic profile of the sustained-release solid dispersions. These studies indicated a prolonged release of Glimepiride, resulting in a more stable and sustained plasma concentration over an extended period. This pharmacokinetic behavior is highly desirable as it reduces the frequency of dosing, thus improving patient compliance and ensuring a consistent therapeutic effect.

Additionally, the sustained-release solid dispersion of Glimepiride exhibited excellent stability under various storage conditions, a crucial factor for its potential commercialization. Stability studies conducted over several months showed no significant degradation of the drug or changes in its release profile, indicating that the formulation is robust and can maintain its efficacy over time.

The patient-centric benefits of this formulation cannot be overstated. By providing a sustained release of Glimepiride, the formulation minimizes the peaks and troughs associated with conventional immediate-release tablets, thereby reducing the risk of hypoglycemia and other side effects. This continuous release mechanism aligns with the body's natural insulin secretion patterns, offering a more physiological approach to managing

type 2 diabetes.

REFERENCES

1. Garber A, Henry RR, Ratner R, Hale P, Chang C, et al. (2011). Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 13(4): 348-356.
2. Ceballos A, Cirrib M, Maestrellib F, Cortib G, Murab P (2005). Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets. Il Farmaco, 60(11-12): 913-918.
3. Bhawandeep Gill (2010). Formulation and evaluation of glimepiride solid dispersion tablets.
4. Asian Journal of Pharmaceutics, 4(3): 212-218.
5. Leuner C, Dressman J (2000). Improving drug solubility for oral delivery using solid dispersions. European Journal of Pharmaceutics and Biopharmaceutics, 50(1-3): 47-60.
6. Nagarajan K, Rao MG, Satyajit D, Pravithra R, Swetha G (2010). Formulation and dissolution studies of solid dispersions of nifedipine. Indian Journal of Novel Drug Delivery, 2(3): 96-98.
7. Mogensen CE (1982). Symposium on Diabetes Mellitus Kidney. Kidney International, 21: 673-675.
8. Emerging Risk Factors Collaboration (2010). Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. The Lancet, 375(9733): 2215-2222.
9. Alberti KG, Zimmet PZ (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet Med, 15(7): 539-553.
10. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, et al. (2011). Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-analysis of randomised controlled trials. BMJ, 26: 343-d4169.
11. Geneva (2006). Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: Report of a WHO/IDF consultation. World Health Organization, 21.
12. Joslin (1936). The Treatment of Diabetes Mellitus. American Journal of the Medical Sciences, 191(1): 127-130.
13. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, et al. (2005). Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health-Syst Pharm, 62(2): 173-181.